ATYPICAL DUCTAL HYPERPLASIA
Clinical trials for ATYPICAL DUCTAL HYPERPLASIA explained in plain language.
Never miss a new study
Get alerted when new ATYPICAL DUCTAL HYPERPLASIA trials appear
Sign up with your email to follow new studies for ATYPICAL DUCTAL HYPERPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug shrink precancerous breast cells before surgery?
Disease control CompletedThis study tested whether a drug called ruxolitinib can reduce abnormal breast cells in people with high-risk or precancerous breast conditions like DCIS or atypical hyperplasia. Half of the 84 participants took ruxolitinib for about 15 days before surgery, and the other half too…
Matched conditions: ATYPICAL DUCTAL HYPERPLASIA
Phase: PHASE2 • Sponsor: Julie Nangia • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Baby tamoxifen shows promise in preventing breast cancer recurrence
Prevention CompletedThis study follows up on women who took a low dose of tamoxifen (5 mg daily) for three years to see if it continues to prevent breast cancer over the long term. The original trial found a 42% reduction in breast cancer events. Researchers will also combine data from three similar…
Matched conditions: ATYPICAL DUCTAL HYPERPLASIA
Sponsor: Ente Ospedaliero Ospedali Galliera • Aim: Prevention
Last updated Jun 27, 2026 11:00 UTC